Overview
Pseudoachondroplasia (PSACH) is a rare skeletal dysplasia characterized by disproportionate short stature, joint laxity, and early-onset osteoarthritis. It is sometimes referred to as pseudoachondroplastic dysplasia or pseudoachondroplastic spondyloepiphyseal dysplasia. Unlike achondroplasia, individuals with pseudoachondroplasia have normal facial features and head size. The condition is caused by mutations in the COMP (cartilage oligomeric matrix protein) gene located on chromosome 19p13.1, which encodes a protein essential for normal cartilage and bone development. The disease is typically not apparent at birth, with affected children appearing normal in length and proportions. Short stature and limb shortening usually become noticeable around age 2 to 3 years, when the child begins walking and growth deceleration becomes evident. Key skeletal features include short limbs (particularly the proximal segments), a waddling gait, lumbar lordosis (exaggerated inward curvature of the lower back), brachydactyly (short fingers), and generalized joint hypermobility, particularly at the knees and fingers. Windswept deformity of the legs (valgus or varus angulation at the knees) is common. Spinal abnormalities may include platyspondyly (flattened vertebral bodies) and anterior beaking of vertebrae. Adult height typically ranges from approximately 82 to 130 cm (about 2.7 to 4.3 feet). Early-onset osteoarthritis, particularly affecting the hips and knees, is a significant source of morbidity and pain, often requiring joint replacement surgery in adulthood. There is currently no cure or disease-modifying therapy for pseudoachondroplasia. Management is supportive and multidisciplinary, focusing on orthopedic surveillance and intervention. Treatment may include surgical correction of lower limb malalignment, management of spinal complications, physical therapy to maintain joint function and muscle strength, and pain management for osteoarthritis. Limb-lengthening procedures may be considered in some cases. Regular monitoring by an orthopedic specialist experienced in skeletal dysplasias is recommended throughout life. Genetic counseling is important for affected individuals and their families.
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for Pseudoachondroplasia.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Pseudoachondroplasia at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Pseudoachondroplasia.
Community
No community posts yet. Be the first to share your experience with Pseudoachondroplasia.
Start the conversation →Latest news about Pseudoachondroplasia
No recent news articles for Pseudoachondroplasia.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Pseudoachondroplasia
What is Pseudoachondroplasia?
Pseudoachondroplasia (PSACH) is a rare skeletal dysplasia characterized by disproportionate short stature, joint laxity, and early-onset osteoarthritis. It is sometimes referred to as pseudoachondroplastic dysplasia or pseudoachondroplastic spondyloepiphyseal dysplasia. Unlike achondroplasia, individuals with pseudoachondroplasia have normal facial features and head size. The condition is caused by mutations in the COMP (cartilage oligomeric matrix protein) gene located on chromosome 19p13.1, which encodes a protein essential for normal cartilage and bone development. The disease is typically
How is Pseudoachondroplasia inherited?
Pseudoachondroplasia follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Pseudoachondroplasia typically begin?
Typical onset of Pseudoachondroplasia is childhood. Age of onset can vary across affected individuals.
Which specialists treat Pseudoachondroplasia?
2 specialists and care centers treating Pseudoachondroplasia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.